These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27312725)

  • 1. Organizational effectiveness: a key to R&D productivity.
    Tollman P; Panier V; Dosik D; Biondi P; Cuss F
    Nat Rev Drug Discov; 2016 Jul; 15(7):441-2. PubMed ID: 27312725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
    Shimura H; Masuda S; Kimura H
    Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can emerging drug classes improve R&D productivity?
    Meier C; Cairns-Smith S; Schulze U
    Drug Discov Today; 2013 Jul; 18(13-14):607-9. PubMed ID: 23702084
    [No Abstract]   [Full Text] [Related]  

  • 4. Mergers and innovation in the pharmaceutical industry.
    Comanor WS; Scherer FM
    J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large drug firms narrow their therapeutic interests.
    Mullard A
    Lancet; 2014 May; 383(9932):1873. PubMed ID: 24892171
    [No Abstract]   [Full Text] [Related]  

  • 6. Combating the cons of consolidation.
    Nat Rev Drug Discov; 2009 Mar; 8(3):177. PubMed ID: 19263592
    [No Abstract]   [Full Text] [Related]  

  • 7. Future pharmaceutical research: the need to look beyond science.
    Seeger S
    Future Med Chem; 2014 May; 6(7):721-3. PubMed ID: 24941866
    [No Abstract]   [Full Text] [Related]  

  • 8. Pfizer's home remedy.
    Abkowitz A
    Fortune; 2009 Aug; 160(4):82-4, 86. PubMed ID: 19728588
    [No Abstract]   [Full Text] [Related]  

  • 9. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 11. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new application of value-stream mapping in new drug development: a case study within Novartis.
    Heinzen M; Mettler S; Coradi A; Boutellier R
    Drug Discov Today; 2015 Mar; 20(3):301-5. PubMed ID: 25448754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racing to define pharmaceutical R&D external innovation models.
    Wang L; Plump A; Ringel M
    Drug Discov Today; 2015 Mar; 20(3):361-70. PubMed ID: 25448753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An assessment of R&D productivity in the pharmaceutical industry.
    Dimitri N
    Trends Pharmacol Sci; 2011 Dec; 32(12):683-5. PubMed ID: 22030299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-centered drug discovery as the means to improved R&D productivity.
    Raoof AA; Aerssens J
    Drug Discov Today; 2015 Sep; 20(9):1044-8. PubMed ID: 25908579
    [No Abstract]   [Full Text] [Related]  

  • 16. Matchmaking service links up researchers to wallflower drugs.
    Schubert C
    Nat Med; 2010 Jan; 16(1):7. PubMed ID: 20057395
    [No Abstract]   [Full Text] [Related]  

  • 17. Biopharma CRO industry in China: landscape and opportunities.
    Xia C; Gautam A
    Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-access public-private partnerships to enable drug discovery--new approaches.
    Müller S; Weigelt J
    IDrugs; 2010 Mar; 13(3):175-80. PubMed ID: 20191434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design principles for innovative workspaces to increase efficiency in pharmaceutical R&D: lessons learned from the Novartis campus.
    Zoller FA; Boutellier R
    Drug Discov Today; 2013 Apr; 18(7-8):318-22. PubMed ID: 23318251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Models for open innovation in the pharmaceutical industry.
    Schuhmacher A; Germann PG; Trill H; Gassmann O
    Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.